ALCOX Stock Overview Operates as an ophthalmology company in France and internationally. More details
Rewards Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Nicox Historical stock prices Current Share Price €0.31 52 Week High €0.46 52 Week Low €0.14 Beta 0 1 Month Change 3.15% 3 Month Change 36.40% 1 Year Change -30.27% 3 Year Change -85.47% 5 Year Change -92.75% Change since IPO -99.69%
Recent News & Updates
New major risk - Shareholder dilution Jan 16
New major risk - Financial data availability Dec 27
New major risk - Financial data availability Oct 20
New major risk - Share price stability Sep 19
Nicox SA Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Jul 25
No longer forecast to breakeven Jul 21 See more updates
New major risk - Shareholder dilution Jan 16
New major risk - Financial data availability Dec 27
New major risk - Financial data availability Oct 20
New major risk - Share price stability Sep 19
Nicox SA Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Jul 25
No longer forecast to breakeven Jul 21
Nicox S.A. Announces Board Changes Jul 16
New minor risk - Shareholder dilution Jun 23
Nicox S.A., Annual General Meeting, Jun 28, 2024 May 26
High number of new and inexperienced directors May 21
New minor risk - Financial data availability May 07
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA Jan 31
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan Dec 14
New major risk - Revenue and earnings growth Nov 15
New major risk - Share price stability Nov 01
First half 2023 earnings released: €0.13 loss per share (vs €0.39 loss in 1H 2022) Oct 26
New major risk - Revenue and earnings growth Oct 22
Nicox S.A. to Report Q2, 2023 Results on Jul 19, 2023 Jul 22
Full year 2022 earnings released Mar 24
Nicox S.A., Annual General Meeting, Feb 28, 2023 Feb 14
Consensus forecasts updated Jan 20
Nicox S.A., Annual General Meeting, Feb 14, 2023 Jan 09
Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma Nov 08
Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470 Nov 01
Nicox (EPA:COX) Has Debt But No Earnings; Should You Worry? Sep 27
Consensus forecasts updated Sep 23
Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial Sep 19
First half 2022 earnings released: EPS: €0 (vs €0.32 loss in 1H 2021) Sep 17
Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors Jul 29
Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology Jul 07
Nicox S.A., Annual General Meeting, Jun 28, 2022 Jun 14
Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022 Jun 03
Nicox S.A. Announces Executive Changes May 16
Nicox S.A., Annual General Meeting, Jun 14, 2022 May 04
Full year 2021 earnings: EPS exceeds analyst expectations May 01
Price target decreased to €11.50 Apr 27
Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma Apr 11
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China Mar 03
Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries Feb 24
Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Formulation Patent for NCX 470 Feb 22
Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye Feb 08
Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma Dec 16
Price target decreased to €11.67 Dec 14
Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical Trial Suggesting That Once-Daily Dosed NCX 4251 Nov 30
Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induced by Endothelin-1 Oct 01
First half 2021 earnings released Sep 28
Nicox S.A. Announces Results from the NCX 4251 Phase 2B Mississippi Blepharitis Trial Sep 24
High number of new and inexperienced directors Aug 02
Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2B Blepharitis Trial Jul 03
Nicox SA Presented Results from the Dolomites Phase 2 Clinical Trial Showing That NCX 470 Jul 01
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates Jun 25
Nicox SA to Present NCX 470 Dolomites Phase 2 Results in Glaucoma Patients at the World Glaucoma E-Congress 2021 Jun 24
Nicox's Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial Jun 01
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar May 04
Is Nicox (EPA:COX) Using Too Much Debt? Apr 30
U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma Apr 28
Nicox S.A., Annual General Meeting, Apr 14, 2021 Mar 06
Analysts Have Just Cut Their Nicox S.A. (EPA:COX) Revenue Estimates By 11% Mar 02
Full year 2020 earnings released Mar 02
Nicox S.A. to Report Fiscal Year 2020 Results on Mar 01, 2021 Mar 02
Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds Feb 23
Nicox S.A. Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia Dec 23
Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis Dec 15
Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment Dec 11
Nicox S.A. has completed a Follow-on Equity Offering in the amount of €15.000651 million. Dec 06
New 90-day high: €4.11 Nov 13
Nicox SA Initiates Second Phase 3 Trial of NCX 470 in Glaucoma Nov 10
New 90-day low: €3.28 Oct 29
Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis Oct 13
New 90-day low: €3.55 Oct 06
Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial Sep 24
Nicox SA Nicox Announces Senior Management Change Sep 18
First half earnings released Sep 12
Nicox S.A. to Report First Half, 2020 Results on Sep 10, 2020 Sep 11
New 90-day low - €3.58 Jul 30
GHO Capital Fund I LP managed by GHO Capital Partners LLP entered into an agreement to acquire remaining unknown minority stake in VISUfarma B.V from Nicox S.A. (ENXTPA:COX) for €5 million Jul 10 Shareholder Returns ALCOX FR Biotechs FR Market 7D 4.4% 8.0% 1.0% 1Y -30.3% -20.2% 3.4%
See full shareholder returns
Return vs Market: ALCOX underperformed the French Market which returned 3.4% over the past year.
Price Volatility Is ALCOX's price volatile compared to industry and market? ALCOX volatility ALCOX Average Weekly Movement 10.8% Biotechs Industry Average Movement 7.5% Market Average Movement 4.4% 10% most volatile stocks in FR Market 10.0% 10% least volatile stocks in FR Market 2.3%
Stable Share Price: ALCOX's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALCOX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Show more Nicox S.A. Fundamentals Summary How do Nicox's earnings and revenue compare to its market cap? ALCOX fundamental statistics Market cap €20.92m Earnings (TTM ) -€17.36m Revenue (TTM ) €3.57m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ALCOX income statement (TTM ) Revenue €3.57m Cost of Revenue €16.90m Gross Profit -€13.33m Other Expenses €4.03m Earnings -€17.36m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 20:16 End of Day Share Price 2025/02/12 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Nicox S.A. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dylan van Haaften Bryan Garnier & Co Louise Chen Cantor Fitzgerald & Co. Revi Mehrotra Credit Suisse
Show 9 more analysts 
